Cancer Conference Update: What Happened at the 2020 San Antonio Breast Cancer Symposium

Management of HER2-Positive Breast Cancer | Monday, March 8, 2021

• Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer (BC) Receiving Neoadjuvant Systemic Therapy — Mark D Pegram, MD

• Adjuvant and Extended-Adjuvant Therapy for Patients with Localized HER2-Positive BC — Sara M Tolaney, MD, MPH

• Optimizing the Management of HER2-Positive Metastatic BC (mBC) — Sara Hurvitz, MD

• Treatment of HER2-Positive Brain Metastases — Carey K Anders, MD

• Incidence and Management of Adverse Events Associated with HER2-Targeted Therapy — Erika Hamilton, MD

Cases from the Community: Investigators Discuss Emerging Research and Actual Patients with Genitourinary Cancers

Urothelial Bladder Carcinoma | Thursday, March 4, 2021

• Evolving Management of Nonmetastatic Urothelial Bladder Cancer (UBC) — Arjun Balar, MD

• New Directions in the Management of Metastatic Urothelial Bladder Cancer — Elisabeth I Heath, MD

• Emerging Data for Treatment of Metastatic Urothelial Carcinoma — Jonathan E Rosenberg, MD

Renal Cell Carcinoma | Monday, March 1, 2021

• Management Issues For Patients with Advanced Renal Cell Carcinoma — Thomas E Hutson, DO, PharmD

• Newly Approved Front-Line Regimens for Metastatic RCC — Thomas Powles, MBBS, MRCP, MD

Prostate Cancer | Thursday, February 25, 2021

• Management of Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) — Tanya B Dorff, MD

• Therapeutic Options for Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) — Fred Saad, MD

• Current and Future Management Paradigms for Metastatic Castration-Resistant Prostate Cancer — A Oliver Sartor, MD

• Integration of PARP Inhibitors into the Management of Metastatic Castration-Resistant Prostate Cancer — Matthew R Smith, MD, PhD

Recent Advances in Hematologic Oncology: A 4-Part Live Webinar Series Reviewing Key Data and Presentations from the 62nd ASH Annual Meeting

Part 1 — Acute Myeloid Leukemia | Wednesday, January 20, 2021

• Optimizing the management of AML in older patients or those ineligible for intensive chemotherapy — Andrew H Wei, MBBS, PhD

• Management of newly diagnosed and previously treated AML with IDH mutations — Eytan M Stein, MD

• Other novel agents and investigational strategies for patients with AML — Daniel A Pollyea, MD, MS

Part 2 — Hodgkin and Non-Hodgkin Lymphoma | Wednesday, February 3, 2021

• Optimal management of newly diagnosed and relapsed/refractory (R/R) follicular lymphoma (FL) — John P Leonard, MD

• Available and emerging approaches for mantle cell lymphoma (MCL) — Michael E Williams, MD, ScM

• Selection and sequencing of therapies for patients with advanced Hodgkin lymphoma (HL) — John Kuruvilla, MD

Cases from the Community: Investigators Discuss Emerging Research and Actual Patients with Gastrointestinal Cancers

Colorectal Cancer | Thursday, February 11, 2021

• New Developments in the Use of Biomarker-Based Treatment for Metastatic Colorectal Cancer (mCRC) — Kristen K Ciombor, MD, MSCI

• Key Considerations in the Selection and Sequencing of Therapies for Patients with mCRC; Novel Investigational Approaches — Eric Van Cutsem, MD, PhD

Gastroesophageal Cancers | Thursday, February 4, 2021

• Optimal Management of HER2-Positive and FGFR2-Positive Gastroesophageal Cancers — Daniel Catenacci, MD

• Evolving Front-Line Management of Advanced Gastric/Gastroesophageal Junction (GEJ) Cancer — Yelena Y Janjigian, MD

• Selection and Sequencing of Therapies for Relapsed Gastric/GEJ Cancer; Novel Investigational Approaches — Rutika Mehta, MD, MPH

• Key Findings Informing the Treatment of Localized and Advanced Esophageal Cancer — Zev Wainberg, MD, MSc

Hepatocellular Carcinoma | Wednesday, January 27, 2021

• New Directions in the Management of HCC — Richard S Finn, MD

• Selection and Sequencing of Treatment for Patients with Relapsed HCC — Tim Greten, MD

• Considerations for the Treatment of HCC in Special Patient Populations — James J Harding, MD

• Front-Line Management for Advanced Hepatocellular Carcinoma — Ahmed Omar Kaseb, MD, CMQ

Year in Review: Clinical Investigators Provide Perspectives on the Most Relevant New Publications, Data Sets and Advances in Oncology

Breast Cancer | Tuesday, February 9, 2021

• Year in Review: ER-Positive Breast Cancer, PARP Inhibitors and Sacituzumab Govitecan — Harold J Burstein, MD, PhD

• 2020 Year in Review: Breast Cancer — Lisa Carey, MD

Bladder Cancer and Renal Cell Carcinoma | Tuesday, February 2, 2021

• Urothelial Bladder Cancer — Sumanta K Pal, MD

• Renal Cell Carcinoma — David I Quinn, MBBS, PhD

Multiple Myeloma | Thursday, January 28, 2021

• Customized Induction and Maintenance Approaches for Newly Diagnosed MM; Select New Developments in Relapsed/Refractory Disease — Rafael Fonseca, MD

• Newly Approved and Promising Investigational Agents for Patients with Relapsed/Refractory MM — Jonathan L Kaufman, MD

Targeted Therapy for Lung Cancer | Tuesday, January 26, 2021

• Early Stage and Targeted Therapy in NSCLC — Joel W Neal, MD, PhD

• Year in Review in Non-Small Cell Lung Cancers — Paul K Paik, MD

Chronic Lymphocytic Leukemia | Thursday, January 21, 2021

• Approved and Investigational BTK Inhibitors in the Management of Chronic Lymphocytic Leukemia (CLL) — Matthew S Davids, MD, MMSc

• Role of Bcl-2 Inhibition in CLL Treatment; Promising Novel Agents and Strategies — Jennifer Woyach, MD

Nontargeted Therapy for Lung Cancer | Tuesday, January 19, 2021

• Locally Advanced and Metastatic NSCLC — Matthew Gubens, MD, MS

• Small Cell Lung Cancer and Mesothelioma — Suresh S Ramalingam, MD

Lymphomas | Thursday, January 14, 2021

• Follicular Lymphoma and Mantle Cell Lymphoma — Christopher R Flowers, MD, MS

• Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma — Sonali M Smith, MD

Gynecologic Cancers | Tuesday, January 12, 2021

• Management of Ovarian Cancer — Robert L Coleman, MD

• Treatment of Endometrial and Cervical Cancers — Richard T Penson, MD, MRCP

Acute Myeloid Leukemia and Myelodysplastic Syndromes | Tuesday, January 5, 2021

• Updates on Treating MDS and Secondary AML — Mikkael A Sekeres, MD, MS

• Year In Review: Acute Myeloid Leukemia — Richard M Stone, MD

Year in Review: Clinical Investigators Provide Perspectives on the Most Relevant New Publications, Data Sets and Advances in Oncology

Hepatobiliary and Pancreatic Cancers | Tuesday, December 15, 2020

• Hepatocellular Carcinoma (HCC) — Lipika Goyal, MD, MPhil

• Cholangiocarcinoma and Pancreatic Cancer — Tanios Bekaii-Saab, MD

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Breast Cancer

HER2-Positive Breast Cancer | Thursday, December 10, 2020

• Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer (BC) Receiving Neoadjuvant Systemic Therapy — Mark D Pegram, MD

• Adjuvant and Extended-Adjuvant Therapy for Patients with Localized HER2-Positive BC — Sara M Tolaney, MD, MPH

• Optimizing the Management of HER2-Positive Metastatic BC (mBC) — Sara Hurvitz, MD

• Treatment of HER2-Positive Brain Metastases — Carey K Anders, MD

• Incidence and Management of Adverse Events Associated with HER2-Targeted Therapy — Erika Hamilton, MD

Triple-Negative Breast Cancer | Friday, December 11, 2020

• Optimal Integration of Immune Checkpoint Inhibitors into the Management of Metastatic Triple-Negative Breast Cancer (mTNBC) — Professor Peter Schmid, MD, PhD

• Novel Applications of Immune Checkpoint Inhibitors for Patients with Early TNBC — Hope S Rugo, MD

• Current and Future Role of PARP Inhibitors for Patients with TNBC and a BRCA Mutation — P Kelly Marcom, MD

• Current and Future Management of PD-L1-Negative mTNBC — Joyce O’Shaughnessy, MD

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Hematologic Cancers

Multiple Myeloma | Friday, December 4, 2020

• Induction therapy for patients with newly diagnosed disease — Robert Z Orlowski, MD, PhD

• Consolidation and maintenance therapy — Rafael Fonseca, MD

• Selection and sequencing of available therapies for relapsed/refractory disease — Nikhil C Munshi, MD

• Chimeric antigen receptor T-cell therapy — Edward A Stadtmauer, MD

• Other novel strategies — Ola Landgren, MD, PhD

Chronic Lymphocytic Leukemia | Friday, December 4, 2020

• First-line treatment options for younger, fit patients — Paul M Barr, MD

• Up-front management of chronic lymphocytic leukemia in older patients or those with comorbidities — Stephan Stilgenbauer, MD

• Optimal management of adverse events with BTK and Bcl-2 inhibitors — Matthew S Davids, MD, MMSc

• Selection and sequencing of therapies for relapsed/refractory disease — Kerry Rogers, MD

• Novel strategies under investigation — Tanya Siddiqi, MD

Acute Myeloid Leukemia | Friday, December 4, 2020

• Optimizing the management of AML in older patients or those ineligible for intensive chemotherapy — Andrew H Wei, MBBS, PhD

• Treatment options for patients with AML harboring FLT3 mutations — Alexander Perl, MD

• Management of newly diagnosed and previously treated AML with IDH mutations — Eytan M Stein, MD

• Tailoring induction and maintenance therapy for younger patients with AML without targetable tumor mutations — Mark Levis, MD, PhD

• Other novel agents and investigational strategies for patients with AML — Daniel A Pollyea, MD, MS

Hodgkin and Non-Hodgkin Lymphoma | Friday, December 4, 2020

• Evolving treatment paradigm for patients with diffuse large B-cell lymphoma (DLBCL) — Ann S LaCasce, MD, MMSc

• Optimal management of newly diagnosed and relapsed/refractory (R/R) follicular lymphoma (FL) — John P Leonard, MD

• Available and emerging approaches for mantle cell lymphoma (MCL) — Michael E Williams, MD, ScM

• Selection and sequencing of therapies for patients with advanced Hodgkin lymphoma (HL) — John Kuruvilla, MD

• Advances in chimeric antigen receptor T-cell therapy for DLBCL and other lymphoma subtypes — Jonathan W Friedberg, MD, MMSc